The company announced the collaborations this week in conjunction with the annual American Society for Mass Spectrometry Conference in Atlanta.
Bruker signed a codevelopment and comarketing agreement with PreOmics for sample prep, and a partnership with Genedata for proteomics software.
Cancer Moonshot-funded teams are profiling pre-cancers in an effort to establish targeted treatment, detection, and prevention methods that can be applied before cancers form.
A LIMS1 gene variant appeared to coincide with increased risk of allograft rejection in kidney transplant recipients.
The facility will be mass spec-focused and comprise a service contract lab for developing protein tests and a CAP- and CLIA-certified lab for offering them.
The company will use the funds to expand its operations across the US, Europe, and Asia as well as to support the launch of new single-cell protein assays.
The company also announced that its board of directors has authorized payment of a quarterly cash dividend of $0.04 per share of its common stock.
The company posted Q1 revenues of $12.3 million, up from $7.5 million in Q1 2018 and above the consensus Wall Street estimate of $10.2 million.
The startup will sell tools and services based on the Nucleic Acid Programmable Protein Array technology developed by Biodesign researcher Joshua LaBaer.
Year-over-year revenues increased on strong demand for the company's Helios and Hyperion imaging mass cytometry systems.
The firm said total revenues rose to $461.4 million from $431.7 million in the first quarter of 2018, beating analysts' consensus estimate of $450.1 million.
Agilent has agreed to provide customized high-fidelity oligo microarrays for the nucleic acid detection step in SomaLogic's Somascan assay.
Caprion said that the acquisition helps it acquire expertise in the analysis of myeloid-derived suppressor cells and expand its geographic coverage.
In work presented at the recent American Association for Cancer Research annual meeting, they found that T-cell cytokine production predicted patient response.
With genomic and proteomic profiles for more than 100 colon cancer cases, researchers identified drug targets, treatment resistance insights, potential cancer drivers, and more.
The German research products firm attributed the higher revenues to organic growth, as well as the impact of recent acquisitions such as TGR Biosciences.
Roche ran a mock clinical trial in which it used DIA mass spec and targeted proteomics to profile 30 colorectal cancer samples under GCP conditions.
The company posted revenues of $513.9 million for the quarter compared to $530.7 million in Q1 2018, below the average Wall Street estimate of $545.3 million.
Investigators identified a set of inflammatory proteins that appears to coincide with current and future risk of end-stage renal disease in individuals with diabetes.
The companies will combine their respective technologies to develop mass spectrometry-based proteomics assays for adverse pregnancy outcomes.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.